Featuring an interview with Dr Adrienne G Waks, including the following topics:

• The Phase III AFT-38 PATINA trial of palbociclib combined with anti-HER2 therapy for hormone receptor (HR)-positive/HER2-positive metastatic breast cancer (mBC) (0:00)
• Role of immunotherapy in the treatment of breast cancer (8:30)
• Defining ER-low breast cancer and identifying treatment approaches for this histologic subtype (15:55)
• Genomic testing approaches for patients with localized breast cancer and identification of candidates for treatment with adjuvant olaparib (19:37)
• Current role of anthracyclines in the treatment of localized breast cancer (31:17)
• Available and novel antibody-drug conjugates for the treatment of breast cancer (41:21)
• Palbociclib with endocrine therapy compared to chemotherapy induction followed by endocrine therapy maintenance for HR-positive, HER2-negative mBC (51:53)

CME information and select publications